Ben Wiegand, global head of the World without Disease Accelerator at Janssen, the Pharmaceutical Companies of Johnson & Johnson, talks about efforts to prevent a disease or to identify it in its earliest stages for more effective treatments.
Welcome to Scientific American’s Science Talk, posted on February 27, 2020. I’m Steve Mirsky. On this episode:
[WIEGAND CLIP]
That’s Ben Wiegand. He received a doctorate in physical chemistry from Harvard. You may have seen bumper stickers that say, “Honk if You Passed P. Chem.” Wiegand is now the Global Head of the World without Disease Accelerator, the WWDA, at Janssen, the Pharmaceutical Companies of Johnson & Johnson, where he’s involved in multiple efforts to prevent disease or identify it in its earliest stages for more effective treatments. We spoke by phone.
On supporting science journalism
If you're enjoying this article, consider supporting our award-winning journalism by subscribing. By purchasing a subscription you are helping to ensure the future of impactful stories about the discoveries and ideas shaping our world today.
[WIEGAND SEGMENT]
That’s it for this episode. Get your science news at our Website (www.scientificamerican.com.), where we’re bringing you the latest news and insights about coronavirus.
And don’t forget to follow us on Twitter, where you’ll get a tweet whenever a new item hits the Web site. Our twitter name is @sciam. For Scientific American’s Science Talk, I’m Steve Mirsky. Thanks for clicking on us.
It’s Time to Stand Up for Science
If you enjoyed this article, I’d like to ask for your support. Scientific American has served as an advocate for science and industry for 180 years, and right now may be the most critical moment in that two-century history.
I’ve been a Scientific American subscriber since I was 12 years old, and it helped shape the way I look at the world. SciAm always educates and delights me, and inspires a sense of awe for our vast, beautiful universe. I hope it does that for you, too.
If you subscribe to Scientific American, you help ensure that our coverage is centered on meaningful research and discovery; that we have the resources to report on the decisions that threaten labs across the U.S.; and that we support both budding and working scientists at a time when the value of science itself too often goes unrecognized.
